Enlivex Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Enlivex Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-28.3%
Buyback Yield
| Total Shareholder Yield | -28.3% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ENLV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENLV's dividend payments have been increasing.
Dividend Yield vs Market
| Enlivex Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ENLV) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ENLV) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ENLV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENLV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ENLV's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ENLV has not reported any payouts.